Related Experiment Video

Updated: Nov 11, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Olaparib for the treatment of metastatic prostate cancer

Corinne Maurice Dror1, Alexander W Wyatt2,3, Kim N Chi1,2

  • 1BC Cancer, Vancouver, Vancouver, BC, V5Z 4S6, Canada.

Future Oncology (London, England)
|March 26, 2021
PubMed

Insights

New treatments for metastatic prostate cancer show promise, but more options are needed. DNA repair gene alterations are common in metastatic castrate-resistant prostate cancer (mCRPC), making PARP inhibitors like olaparib a key therapeutic strategy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Metastatic prostate cancer remains a significant cause of cancer mortality.
  • Advances in understanding molecular pathways have identified new therapeutic targets.
  • Homologous recombination repair (HRR) gene alterations are found in approximately 25% of metastatic castrate-resistant prostate cancer (mCRPC) cases.

Purpose of the Study:

  • To review the current evidence for poly-ADP-ribose polymerase (PARP) inhibition in mCRPC treatment.
  • To focus specifically on the efficacy and application of olaparib in mCRPC.

Main Methods:

  • Literature review of clinical trials and studies on PARP inhibitors in mCRPC.
  • Analysis of data concerning olaparib's effectiveness in patients with HRR gene alterations.

Main Results:

  • PARP inhibition, particularly with olaparib, has demonstrated clinical benefit in mCRPC patients with HRR gene alterations.
  • Olaparib is approved for treating mCRPC harboring specific DNA repair gene mutations.

Conclusions:

  • Targeting DNA repair pathways with PARP inhibitors represents a significant advancement in mCRPC therapy.
  • Olaparib is an effective treatment option for a subset of mCRPC patients with homologous recombination repair deficiencies.
Keywords:
ATMBRCA1/2CDK12PARP inhibitiongenomic alterationshomologous recombination repairmetastatic prostate cancerolaparib

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
320
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K